ESMO 2022: Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 Trial
Share.
About Author
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
